Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

ASCO 2024: Advances in NSCLC

Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo

ASCO 2024: Advances in NSCLC ( Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo )

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

Clinical behaviour of breast cancer in young BRCA carriers and prognostic...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Chemotherapy before and after surgery may be new standard treatment for some...

Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer ( Prof Jens Hoeppner - University of Bielefeld, Bielefeld, Germany )

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging...

Dr Natalia Neparidze - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post...

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado

Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )

More from ecancer